Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Journal of the National Comprehensive Cancer Network : JNCCN|April 12, 2012
Locally recurrent endometrial cancer: a case reportSrinivas K Tantravahi, Theresa L Werner
Current Hematologic Malignancy Reports|August 31, 2017
Minimal Residual Disease Eradication in CML: Does It Really Matter?Srinivas K Tantravahi, Raga S Guthula, Thomas O'Hare, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2024
Chronic Myelomonocytic Leukemia and Atypical Chronic Myeloid Leukemia: A National AnalysisVictoria A Vardell, Jennifer Ose, Anton V Rets, et al.
Blood Neoplasia|March 9, 2026
Mutant calreticulin-directed immunotherapies in myeloproliferative neoplasmsWilliam L Heaton, Matthew T Jenkins, Nicole S Arellano, et al.
American Journal of Clinical Oncology|May 15, 2014
Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysisArati Dahal, Brandon K Bellows, Guru Sonpavde, et al.
American Journal of Hematology|October 21, 2022
Impact of academic medical center access on outcomes in multiple myelomaVictoria A Vardell, Daniel A Ermann, Srinivas K Tantravahi, et al.
Journal of Health Economics and Outcomes Research|August 19, 2025
Real-World Prevalence and Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors in the US: A Retrospective Claims Database AnalysisSrinivas K Tantravahi, Dominick Latremouille-Viau, Raj Desai, et al.
Blood Advances|October 25, 2019
The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterationsAnca Franzini, Anthony D Pomicter, Dongqing Yan, et al.
Clinical Genitourinary Cancer|January 20, 2016
Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic TherapiesShiven B Patel, David D Stenehjem, David M Gill, et al.
The Lancet. Haematology|May 16, 2022
Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 studyNaveen Pemmaraju, Jacqueline S Garcia, Jalaja Potluri, et al.
Pageof 3